<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; tool</title>
	<atom:link href="http://www.tapanray.in/tag/tool/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Should India allow use of Compulsory License as a common tool to improve access to medicines?</title>
		<link>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines</link>
		<comments>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/#comments</comments>
		<pubDate>Mon, 20 Aug 2012 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[allow]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=48</guid>
		<description><![CDATA[Compulsory License (CL) is generally considered a very important provision in the Patent Act of a country to protect public health interest not only by the governments, but also by a large number of experts across the globe and the &#8230; <a href="http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Social Media – an evolving new-age powerful communication tool for the Pharmaceutical Industry, both global and local</title>
		<link>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local</link>
		<comments>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/#comments</comments>
		<pubDate>Mon, 20 Dec 2010 01:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[both]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[Facebook financial]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[new-age]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[powerful]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[tool]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=332</guid>
		<description><![CDATA[David Edelman in his article titled, &#8220;Branding in the Digital Age:You&#8217;re Spending your Money in All the Wrong Places&#8221;, published in the &#8216;Harvard Business Review&#8217;  dated December 2010, commented the following: &#8220;Consumers today connect with brands in fundamentally new ways, often &#8230; <a href="http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative use of the new-age ‘Social cyber-media’ as a pharmaceutical marketing tool has the potential to open a goldmine of opportunities.</title>
		<link>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities</link>
		<comments>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/#comments</comments>
		<pubDate>Thu, 25 Jun 2009 01:30:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[goldmine]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[new-age]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=851</guid>
		<description><![CDATA[The new-age marketing tool: With more and more doctors not giving adequate time and even showing reluctance to meet the medical representatives and the important hospitals following suit, the global pharmaceutical companies are now in search of new marketing tools. &#8230; <a href="http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
